FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,115 | -55.5% | 16,092 | 0.0% | 0.00% | -57.1% |
| Q2 2023 | $76,598 | -53.5% | 16,092 | -44.3% | 0.01% | -56.2% |
| Q1 2023 | $164,587 | -43.5% | 28,875 | 0.0% | 0.02% | -46.7% |
| Q4 2022 | $291,349 | -55.5% | 28,875 | -1.0% | 0.03% | -55.2% |
| Q3 2022 | $654,000 | +3.0% | 29,178 | +13.8% | 0.07% | +6.3% |
| Q2 2022 | $635,000 | -35.9% | 25,645 | +0.4% | 0.06% | -25.0% |
| Q1 2022 | $990,000 | -33.0% | 25,545 | +1.1% | 0.08% | -29.4% |
| Q4 2021 | $1,478,000 | +0.7% | 25,257 | +2.0% | 0.12% | -9.2% |
| Q3 2021 | $1,467,000 | -31.7% | 24,758 | +0.1% | 0.13% | -33.8% |
| Q2 2021 | $2,147,000 | +19.0% | 24,738 | +13.1% | 0.20% | +11.9% |
| Q1 2021 | $1,804,000 | -10.5% | 21,878 | -1.3% | 0.18% | -17.3% |
| Q4 2020 | $2,016,000 | +39.5% | 22,166 | -38.7% | 0.21% | +19.6% |
| Q3 2020 | $1,445,000 | +1.7% | 36,153 | -12.7% | 0.18% | +2.9% |
| Q2 2020 | $1,421,000 | +61.7% | 41,407 | +4.6% | 0.17% | +56.8% |
| Q1 2020 | $879,000 | -31.2% | 39,599 | -39.3% | 0.11% | -1.8% |
| Q4 2019 | $1,278,000 | – | 65,286 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |